To develop a near-infrared spectroscopic method to identify breast cancer biomarkers and to retrospectively determine if benign and malignant breast lesions could be distinguished by using this method.
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Kukreti et al this study was constructed in a university laboratory by using National Institutes of Health grants. These patents are owned by the University of California. B.J.T. and A.E.C. are members of a scientifi c advisory board for Volighten (Irvine, Calif ) and hold stock in this company. They have licensed these patents to Volighten through the University of California, Irvine. They assert that (a) this study was completed prior to the formation of the company Volighten, (b) they were not involved with Volighten during the acquisition, processing, and analysis of the results presented in this study, and (c) this study was completed without any infl uence by Volighten. Volighten provided no support (fi nancial or other) toward this study.
Patients
All patients provided written informed consent to participate in the study in strict adherence to a protocol approved by an institutional review board of the University of California, Irvine . The diffuse optical imaging used to depict breast tumors and monitor tumor response to therapy ( 19, 20 ) . Diffuse optical spectroscopy (DOS) imaging, by increasing the wavelength range and resolution, helps measure not only the abundance of hemoglobin but also bulk lipids and water ( 21 ) . DOS imaging has been used to characterize malignant tumors and tumor response to chemotherapy (22) (23) (24) . However, tumor characterization by using these components (hemoglobin, water, and bulk lipids) has not been found to be specifi c for malignancy: The abundance of these tissue chromophores is not a unique cancer-specifi c signature ( 16, 21, 25 ) . Furthermore, age and hormonal status introduce high interpatient variability in NIR absorption spectra and complicate diagnosis when only the magnitude of tissue absorption is used ( 24, 26, 27 ) . Through the application of a spectral analysis method that accounts for interpatient variability, we have discovered metabolic differences between malignant and normal tissues that result from subtle changes in molecular disposition ( 28 ) . Our purpose was to demonstrate how absorption signatures, likely resulting from changes in lipid, hemoglobin, and water metabolism, rather than the abundance of molecules, help distinguish between benign and malignant breast tumors.
Materials and Methods
B.J.T., A.E.C., S.K., and E.G. report that they hold patents related to the technology and analysis methods described in this study. The particular DOS imaging instrumentation used in S pectroscopic results add functional and molecular -specifi c information to imaging. For example, several in vivo magnetic resonance (MR) spectroscopy studies (1) (2) (3) (4) (5) (6) (7) (8) (9) have shown that tumors exhibit peaks at 3.2 ppm in hydrogen 1 spectra of breast tissue that correspond to elevated levels of total choline which are known to be more abundant in active tumors. MR spectroscopy may improve diagnostic accuracy in the distinction between malignant and benign tumors and help predict therapeutic response in treated tumors (10) (11) (12) .
Diffuse optical imaging is commonly used to provide biochemical infor mation on hemoglobin concentration by measuring near-infrared (NIR) tissue absorption (13) (14) (15) (16) (17) (18) . Studies have shown
Implications for Patient Care
DOS imaging with the SRDS n method may be used in conjunction with other radiologic imaging to characterize abnormal regions in the breast.
The application of DOS imaging n with the SRDS method is simple to perform and can be provided at bedside or with portable technology.
Advances in Knowledge
A self-referencing differential n spectroscopy (SRDS) method has been developed for near-infrared (NIR) (650-1000 nm) diffuse optical spectroscopic (DOS) imaging in tissues that accounts for the unique metabolism of individual patients and facilitates comparisons across patient populations.
The SRDS method exploits the n presence or absence of a spectral fi ngerprint that reports on molecular disposition-the location, concentration , and environment of a molecular speciesand not molecular abundance of NIR absorbers in tissues (hemoglobin, water, and lipids).
DOS imaging measurements of n breast lesions display unique endogenous spectral absorption fi ngerprints, called specifi c tumor components (STCs), that separate lesions from normal breast tissues.
A weighted wavelength analysis n method was developed to exploit the entire STC absorption spectrum in the NIR to discriminate between benign and malignant tumors. Of the remaining subjects, the average DOS imaging measurement took place 32 days 6 16 (standard deviation) after biopsy (minimum, 14 days).
In the fi broadenoma population, fi ve of 17 patients were measured prior to undergoing biopsy. The average DOS imaging measurement date was 344 days 6 440 after undergoing biopsy (minimum, 40 days).
Instrumentation
The DOS instrument, which uses a combined frequency-domain and continuous-wave tissue spectrometer, has been previously described ( 29-31 ). The combined system is necessary to provide absorption and scattering spectra from 650 to 1000 nm (approximately 1000 wavelengths with 8-nm spectral resolution). The frequency-domain light sources are six independent laser diodes (660, 690, 780, 808, 830, and 850 nm), while the continuous-wave light source is a tungsten-halogen lamp. Frequencymodulated light was detected by using an avalanche photodiode detector, and continuous-wave light was detected by using a back-illuminated spectrometer.
A handheld probe incorporates source (ie, optical fi bers) and detector (ie, enoma population age was signifi cantly younger than the normal ( P = .04) and malignant ( P = .001) age populations. For a subset group of fi ve subjects randomly selected, data were reanalyzed by using a different set of normal tissue as the internal control. We stress that the algorithm takes into account the functional backgrounds of the patients and in principle accounts for age-dependent physiologic effects.
In the control population, 13 were premenopausal, one was perimenopausal, and the remaining seven were postmenopausal.
The selection criteria for DOS imaging were mainly a function of patient convenience. Not all patients in the University of California, Irvine breast clinic were scanned with DOS; patients came to the Beckman Laser Institute and arranged for the DOS imaging independently of their medical treatment. Thus, the 60 subjects were not consecutive patients seen in the University of California, Irvine breast clinic.
DOS imaging measurements were generally obtained prior to or 4 weeks after biopsy to avoid artifacts from bruising. Great care was taken to ensure that the observed DOS imaging signals were not because of biopsy effects. In the malignant population, study was compliant with the Health Insurance Portability and Accountability Act. From a search of patient records dating from August 2004 to January 2007, DOS imaging data for 60 subjects were selected; there were 22 malignant tumors, 18 benign tumors (17 patients), and 21 control subjects. Selection criteria from the protocol were as follows: female, older than 21 years, not pregnant, not taking lightsensitive medications, and gave written informed consent. In addition, for patients with lesions, the subject must have had a suspicious fi nding on a mammogram or sonogram prior to enrollment in the study. All subjects had palpable lesions. Patients were generally referrals from a physician (D.H .).
Tumor disease was confi rmed by using standard of care biopsy results, and control subjects had normal mammographic fi ndings. All subjects were women (age range, 22-74 years). Within each group, mean age and range were as follows ( There was no signifi cant age difference between normal and malignant populations ( P = .14). However, the fi broad- Laser breast scanner has a handheld probe which is placed in gentle contact with the breast during data acquisition. DOS imaging measurements were obtained in both breasts, point by point over a series of lines marked at 10-mm intervals. For the tumor-containing breast, DOS imaging measurements were taken over tumor and surrounding normal tissues. Similar measurements were taken on the mirrored location of the contralateral breast.
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Kukreti et al 1. Sensitivity, specifi city, positive predictive value, and negative predictive value were calculated on the basis of accuracy in benign or malignant classifi cation. Additional statistical calculations were performed by using commercial software (JMP IN; SAS Institute, Cary, NC). Nonparametric statistics were used to calculate spectral differences between benign and malignant populations (Wilcoxon rank sum test). Signifi cance was assumed at a confidence interval of 95% ( a = .05) for a two-tailed distribution. All spectral error bars are those for the population.
We analyzed the effect of including an increasing number of spectra in calculating the average. The "score" (ie, the separability of fi broadenoma from cancer) converges to a constant value as the number of patients used for the average was increased. Therefore, we concluded that adding more patients will not further decrease the separability. After a data set of 20, we started to reach a plateau, which is suffi cient to separate fi broadenoma from cancer.
The data set was subjected to a round-robin analysis to determine the dependence of the classifi cation of the patients according to the malignancy index on the particular set. Each patient was systematically omitted from the set. For each of the reduced sets (one patient omitted), the weighting factors were optimized. The malignancy index for the omitted patient was calculated according to the new weights as if this patient was unknown. We found that the malignancy index changed slightly for each patient. However, no patient changed classifi cation as a result of this round-robin analysis.
were calculated from a spectral model of tissue absorption by using the basis spectra ( Fig 2 ) . For the self-referencing differential spectroscopy (SRDS) method, the absorption spectra were further analyzed by using custom software (Elantest; Laboratory for Fluorescence Dynamics, Irvine, Calif, www.lfd.uci. edu ). Details of the SRDS method, also known as the double-differential method, have been described ( 28 ) . Briefl y, the SRDS method depicts spectral components not accounted for by the basis absorber spectra ( Fig 2 ) by eliminating patient-specifi c spectral variations from scatter-corrected absorption spectra. The unaccounted spectral components are called collectively the specifi c tumor component (STC) spectrum, because these STC spectra are found only in lesions and not in normal tissues. The STC represents tissue absorption associated with the molecular disposition of NIR absorbers in tissues. STC spectra were recovered over an average of spatial points for patients with tumors in both lesion and normal areas (see Appendix E1 [online]).
Statistical Analysis
STC spectra for malignant and benign tumors were distinguished by using a custom spectral separation method (see Appendix E1 [online]). In brief, the algorithm maximizes differences in spectral shape by weighting different wavelength regions. For every patient (for each spectrum), the "similarity" from the average STC spectrum of a benign and a malignant lesion was cal culated and translated into an index (ie, the malignancy index), which ranged from 2 1 to avalanche photodiode detector and a spectrometer detector fi ber) channels ( Fig 1 ) . Less than 20 mW of optical power was launched into the tissue at any time by using refl ection geometry (28-mm source detector separation). Frequencydomain measurements were calibrated with a tissue-simulating phantom with known absorption and scattering properties. Spectral response was calibrated by using a commercial refl ectance standard (Spectralon, Labsphere, North Sutton, NH).
Measurement Procedure
DOS imaging measurements were acquired by moving the handheld probe over the tumor in lines of discrete measurement points spaced 10 mm apart ( Fig 1 ) . Tumor locations were known a priori from mammographic fi ndings, ultrasonographic (US) fi ndings, and/or palpation. Patients were measured in the supine position. Probe contact was similar to that at US, by using gentle contact on the breast without compression. Full broadband absorption and reduced scattering spectra were measured at each spatial location, requiring less than 10 seconds per spatial location. Similar measurements were taken on the mirrored location of the contra lateral breast.
Data Analysis
Data were analyzed by using custom software designed for Matlab (Mathworks, Natick, Mass). For each measured breast location, frequency-domain and continuous-wave data were processed to recover scatter-corrected absorption spectra from 650 to 1000 nm ( 24 
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Results
NIR Tumor Characteristics
In Figure 3 , we show an example of NIR absorption spectra averaged over a line of points from tumor-containing and normal tissues. The overall absorption is higher across the spectrum for tumor tissue than that for normal tissue. The increased absorption below 850 nm is attributed to increases in oxy-and deoxyhemoglobin (13) (14) (15) 24, 32 ) . These spectral changes originate from electronic transitions in molecular states. The increased absorption near 960 nm is due to O-H vibrational overtones, which are primarily due to water. Tissue absorption near 930 nm is representative of vibrational overtones of lipid C-H bonds. These spectral features have been documented in a previous study of 58 malignant tumors ( 24 ) .
Specifi c Tumor Spectra
SRDS spectra from representative normal (right breast) and malignant (left breast) tissues were calculated at seven spatial locations ( Fig 4 ) . The SRDS method uncovered spectral signatures that were not accounted for by the traditional NIR basis set, as demonstrated 
Discussion
Increased spectral content improves tissue characterization. The SRDS approach to spectral analysis revealed spectral signatures that contain specifi c absorption bands which separate normal from normal tissue and benign from malignant tissue . To accurately measure these fi ngerprint STC spectra, it is imperative that many individual NIR wavelengths (approximately 1000) are measured across a wide spectral band (650-1000 nm). The amplitudes of the STC spectra are small (about 1% of the total absorption) but well above the signal-to-noise ratio. The STC spectral shapes are highly reproducible and exhibit consistent and specifi c wavelength-dependent characteristics. In STC spectra, the variations in abundance of NIR absorbers resulting from interpatient variances have been effectively subtracted ( 28 ) . This selfreferencing feature is important because NIR absorption spectra are known to mors were correctly classifi ed as benign or malignant.
In Figure 6 , we present a comparison of STC spectra that have been normalized to the amplitude (thereby providing a ratio) to retrieve the differences in spectral shape, as opposed to magnitude, from both benign ( n = 18) and malignant ( n = 22) tumors. Distinctive spectral differences exist between the STC spectra of these populations.
Differential Diagnosis
The average malignancy index values for benign and malignant tumors were 2 0.51 6 0.29 and 0.44 6 0.26, respectively. These means were statistically different ( Z , .0001, Wilcoxon rank sum test, two sided, a = .05). Plotting the malignancy index values for all patients showed a separation between the pathologic states ( Fig 7 ) . The malignancy index was positive for malignant tumors and negative for benign tumors. As shown in Figure 7 , one benign tumor (patient 5) was misclassifi ed as cancer and two cancers (patients 25 and 38) were misclassifi ed as benign. If we use a value of 0.0 as the cutoff point, we would recover a sensitivity and specifi city by the spectral features present in the left (malignant) spectrum but absent in the right (normal) spectrum.
Increases in STC index were localized in the region of the tumor and were not present in normal tissue regions. While these maps are relatively low in spatial resolution, they are highly specifi c for malignancy. Figure 5 presents the STC spectra acquired from 22 malignant breast tumors and the spatially equivalent normal tissue from the same patients, as well as normal regions from 21 control subjects. Despite the wide range in patient age and tumor size, the STC spectrum was present in all 22 tumors and was not found in the normal tissues of any subjects in this study. STC spectra were found in all malignant cases and displayed notable features in the following fi ve wavelength regions: 650-665, 730-800, 875-930, 930-960, and 980-1000 nm ( 28 ) . We note that the specifi c choice of normal region had little effect on the overall shape of the STC spectrum. The STC spectral shapes were similar to the original, and the tu- 
Specifi c Tumor Spectra and Population Distribution
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Kukreti et al olding used by conventional optical detection depends on the magnitude of the physiologic background. By using the STC signature alone, we misclassifi ed three of 40 tumors analyzed in this study (two false-negative fi ndings, one false-positive fi nding). These misclassifi cations in signal may arise from tumor heterogeneity or other unknown spectral components. Additional information from other optical parameters such as concentrations of hemoglobin, water, and bulk lipid may improve classifi cation. Furthermore, DOS imaging may be combined with other imaging modalities to improve sensitivity and specifi city.
On the basis of the wavelength dependence of the STC spectrum, we hypothesize that the signature is due to changes in lipid metabolism. Recent studies ( 10, (33) (34) (35) have shown that cancers can alter the lipid metabolism. Benign lesions such as fi broadenomas display hemodynamic signatures similar to those of malignant lesions ( 16, 25 ) .
There were limitations to the study. Fibroadenomas were the only type of benign tumors measured. Furthermore, the lesions were not corrected for depth.
In conclusion, the SRDS method relies on the presence or absence of a spectral fi ngerprint that reports on molecular disposition and not molecular abundance. These changes in molecular disposition are on the order of parts per thousand and are possibly due to alterations in the lipid state. The SRDS technique subtracts for the unique metabolism of each individual patient and facilitates comparisons across patient populations. We converted the observed molecular dispositions into a simple index that stratifi ed benign and malignant tumors in a population of 40 subjects with lesions. The observation of pathologic statespecifi c spectral signatures provided a potentially signifi cant method for differential diagnosis and monitoring response to therapy.
